SCHEMBL7413330

SCHEMBL7413330

O=C1CCCc2c1ccc1ccccc21

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 1/20 0.48
HSD17B10 Q99714 3/20 0.46
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
CYP2A6 P11509 2/20 0.46
MAOA P21397 1/20 0.46
MAOB P27338 1/20 0.46
ALDH1A1 P00352 4/20 0.45
MAPT P10636 2/20 0.45
NPSR1 Q6W5P4 2/20 0.45
KDM4E B2RXH2 2/20 0.45
CYP1A2 P05177 2/20 0.45
HPGD P15428 2/20 0.45
CYP2C19 P33261 2/20 0.45
GLA P06280 1/20 0.45
CYP2C9 P11712 1/20 0.45
SIRT1 Q96EB6 1/20 0.45
HTT P42858 2/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
CDK5 Q00535 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8016638 0.89 MAOA (0.57) BRD4HSD17B10MEN1KMT2ACYP2A6
SCHEMBL8359592 0.89 HPGD (0.51) HSD17B10MEN1KMT2ACYP2A6ALDH1A1
SCHEMBL9576677 0.80 HPRT1 (0.50) HSD17B10MEN1KMT2ACYP2A6ALDH1A1
SCHEMBL9181184 0.78 KDM4E (0.49) HSD17B10MEN1KMT2ACYP2A6ALDH1A1
SCHEMBL29862069 0.78 KDM4E (0.49) HSD17B10MEN1KMT2ACYP2A6ALDH1A1
SCHEMBL8713855 0.74 HPGD (0.46) HSD17B10MEN1KMT2ACYP2A6ALDH1A1
SCHEMBL8713852 0.74 HPGD (0.46) HSD17B10MEN1KMT2ACYP2A6ALDH1A1
SCHEMBL20457151 0.74 PIM1 (0.38) BRD4HSD17B10MEN1KMT2ACYP2A6
SCHEMBL15467504 0.73 CYP1A2 (0.46) HSD17B10MEN1KMT2ACYP2A6ALDH1A1
SCHEMBL30994678 0.73 HSP90AA1 (0.59) BRD4HSD17B10ALDH1A1MAPTNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3630759-A1 ION CHANNEL INHIBITOR COMPOUNDS FOR CANCER TREATMENT Centre National De La Recherche Scientifique (FR) 2020-04-08 EP disclosed
EP-3328872-B1 ELECTROLUMINESCENT BRIDGED METAL COMPLEXES FOR USE IN ELECTRONIC DEVICES MERCK PATENT GMBH (DE) 2019-05-29 EP disclosed
US-20180226591-A1 ELECTROLUMINESCENT BRIDGED METAL COMPLEXES FOR USE IN ELECTRONIC DEVICES MERCK PATENT GMBH (DE) 2018-08-09 US disclosed
US-20180226591-A1 ELECTROLUMINESCENT BRIDGED METAL COMPLEXES FOR USE IN ELECTRONIC DEVICES MERCK PATENT GMBH (DE) 2018-08-09 US disclosed
EP-3328872-A1 ELECTROLUMINESCENT BRIDGED METAL COMPLEXES FOR USE IN ELECTRONIC DEVICES Merck Patent GmbH (DE) 2018-06-06 EP disclosed
US-7332260-B2 Naphthopyrans annelated in C5-C6, their preparation and compositions and (CO)polymer matrices containing them CORNING INCORPORATED (US) 2008-02-19 US disclosed
US-7332260-B2 Naphthopyrans annelated in C5-C6, their preparation and compositions and (CO)polymer matrices containing them CORNING INCORPORATED (US) 2008-02-19 US disclosed
EP-1100769-B1 AMINOMETHYLCARBOXYLIC ACID DERIVATIVES AKZO NOBEL NV (NL) 2002-12-04 EP disclosed
US-6410592-B1 THERAPY FOR CENTRAL NERVOUS SYSTEM DISORDERS, PSYCHOLOGICAL DISORDERS AKZO NOBEL N.V. (NL) 2002-06-25 US disclosed
EP-0864559-B1 Substituted amino compounds and their use as analgesic active substances GRUENENTHAL GMBH (DE) 2002-06-05 EP disclosed
WO-1996005195-A1 NOVEL N-SUBSTITUTED NAPHTHOFUSED LACTAMS NOVO NORDISK A/S (DK) 1996-02-22 WO disclosed
US-5356935-A Reductase inhibitors ELI LILLY AND COMPANY (US) 1994-10-18 US disclosed
US-5356935-A Reductase inhibitors ELI LILLY AND COMPANY (US) 1994-10-18 US disclosed
US-5326863-A Antithrombin and antitrypsin activity BRISTOL-MYERS SQUIBB COMPANY (US) 1994-07-05 US disclosed
US-5256293-A Immobilizing enantiomer on support effective for use in chromatographic separation RESEARCH CORPORATION TECHNOLOGIES, INC. (US) 1993-10-26 US disclosed
WO-1992019589-A2 LIPOXYGENASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 1992-11-12 WO disclosed
US-5140047-A Antiinflammatory agents SMITHKLINE BEECHAM CORPORATION (US) 1992-08-18 US disclosed
US-4886733-A Photographic products and processes POLAROID CORPORATION (US) 1989-12-12 US disclosed
EP-0097940-B1 PROCESS FOR THE PREPARATION OF ARALIPHATIC ALCOHOLS HOECHST AKTIENGESELLSCHAFT (DE) 1985-04-24 EP disclosed
EP-0097940-A1 Process for the preparation of araliphatic alcohols HOECHST AKTIENGESELLSCHAFT (DE) 1984-01-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180226591-A1 ELECTROLUMINESCENT BRIDGED METAL COMPLEXES FOR USE IN ELECTRONIC DEVICES EED, SOD1, NBAS BRD4 475/4885HSD17B10 2679/4885MEN1 2022/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.